{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:27:04Z","timestamp":1793924824933,"version":"4.8.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015993","name":"Kowa Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jceh.2026.103525","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:22:10Z","timestamp":1772558530000},"page":"103525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Post Hoc Analysis of a Phase 2 Randomized Trial of Pemafibrate in Metabolic Dysfunction\u2013associated Steatotic Liver Disease: Associations With Platelet Count, Liver Stiffness, and Spleen Volume"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8804-2014","authenticated-orcid":false,"given":"Ryohei","family":"Tanigawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Suganami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Tanahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4273-0343","authenticated-orcid":false,"given":"Andrey","family":"Belous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2026.103525_bib1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/apt.17846","article-title":"Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease","volume":"59","author":"Loomba","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2026.103525_bib2","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jceh.2026.103525_bib3","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103525_bib4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S2468-1253(23)00438-7","article-title":"Pathophysiology and therapeutic options for cirrhotic portal hypertension","volume":"9","author":"Guix\u00e9-Muntet","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103525_bib5","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/hematology.2022000408","article-title":"Thrombocytopenia and liver disease: pathophysiology and periprocedural management","volume":"2022","author":"Lim","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jceh.2026.103525_bib6","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.jhep.2022.08.028","article-title":"Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease","volume":"77","author":"Mitten","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103525_bib7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cld.2024.03.001","article-title":"The pathophysiology of portal hypertension","volume":"28","author":"Ramkissoon","year":"2024","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2026.103525_bib8","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.cgh.2018.12.038","article-title":"Patients with signs of advanced liver disease and clinically significant portal hypertension do not necessarily have cirrhosis","volume":"17","author":"Rodrigues","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103525_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1172\/JCI105380","article-title":"Pooling of platelets in the spleen: role in the pathogenesis of \"hypersplenic\" thrombocytopenia","volume":"45","author":"Aster","year":"1966","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jceh.2026.103525_bib10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2026.103525_bib11","article-title":"CT-derived liver and spleen volume accurately diagnose clinically significant portal hypertension in patients with hepatocellular carcinoma","volume":"5","author":"Romero-Crist\u00f3bal","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jceh.2026.103525_bib12","article-title":"CT-derived spleen volume accurately diagnoses severe portal hypertension at HVPG thresholds of 16 mmHg","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jceh.2026.103525_bib13","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/hep.21665","article-title":"Liver stiffness measurement predicts severe portal hypertension in patients with HCV-Related cirrhosis","volume":"45","author":"Vizzutti","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103525_bib14","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.jhep.2016.07.021","article-title":"Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging","volume":"65","author":"Palaniyappan","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103525_bib15","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103525_bib16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jhep.2011.12.008","article-title":"PPAR\u03b1 activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats","volume":"56","author":"Rodr\u00edguez-Vilarrupla","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103525_bib17","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3390\/metabo13050626","article-title":"Novel selective PPAR\u03b1 modulator pemafibrate for dyslipidemia, non-alcoholic fatty liver disease (NAFLD), and atherosclerosis","volume":"13","author":"Yamashita","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.jceh.2026.103525_bib18","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","article-title":"Primary biliary cholangitis","volume":"404","author":"Tanaka","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2026.103525_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","article-title":"Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARMa), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial","volume":"249","author":"Ishibashi","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jceh.2026.103525_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2026.01.008","article-title":"Efficacy for LDL-C\u2013lowering and safety of pemafibrate extended-release formulation in patients with statin-intolerant hypercholesterolemia: a phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group trial","author":"Yamashita","year":"2026","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jceh.2026.103525_bib21","doi-asserted-by":"crossref","first-page":"823","DOI":"10.5551\/jat.65395","article-title":"Effects of pemafibrate on LDL-C and related lipid markers in patients with MASLD: a sub-analysis of the PEMA-FL study","volume":"32","author":"Tanigawa","year":"2025","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jceh.2026.103525_bib22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5551\/jat.64112","article-title":"Efficacy and safety of pemafibrate, a novel selective PPAR\u03b1 modulator in Chinese patients with dyslipidemia: a double-masked, randomized, Placebo- and active-controlled comparison trial","volume":"32","author":"Dai","year":"2025","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jceh.2026.103525_bib23","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/apt.16596","article-title":"Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease","volume":"54","author":"Nakajima","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2026.103525_bib24","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jhep.2022.05.033","article-title":"Porto-sinusoidal vascular disorder","volume":"77","author":"De Gottardi","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103525_bib25","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/liv.13317","article-title":"Thrombocytopenia in chronic liver disease","volume":"37","author":"Peck-Radosavljevic","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2026.103525_bib26","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2517319122","article-title":"Kupffer cells are essential for platelet-mediated thrombopoietin generation in the liver","volume":"122","author":"Karakas","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jceh.2026.103525_bib27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/s12876-025-03967-z","article-title":"Effect of pemafibrate in reducing intestinal long-chain fatty acid absorption and hepatic fibrosis in metabolic dysfunction-associated steatohepatitis rats","volume":"25","author":"Okada","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jceh.2026.103525_bib28","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/jdi.12845","article-title":"Effects of a novel selective peroxisome proliferator-activated receptor \u03b1 modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance","volume":"9","author":"Matsuba","year":"2018","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jceh.2026.103525_bib29","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cmet.2025.04.014","article-title":"FGF21 reverses MASH through coordinated actions on the CNS and liver","volume":"37","author":"Rose","year":"2025","journal-title":"Cell Metab"},{"key":"10.1016\/j.jceh.2026.103525_bib30","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2026.103525_bib31","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jhep.2022.12.025","article-title":"Rational combination therapy for NASH: insights from clinical trials and error","volume":"78","author":"Ratziu","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103525_bib32","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc21-2049","article-title":"Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jceh.2026.103525_bib33","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","author":"Takahashi","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jceh.2026.103525_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.jceh.2026.103525_bib35","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3390\/cells11040720","article-title":"Selective PPAR\u03b1 modulator pemafibrate and sodium-glucose cotransporter 2 inhibitor tofogliflozin combination treatment improved histopathology in experimental mice model of non-alcoholic steatohepatitis","volume":"11","author":"Murakami","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jceh.2026.103525_bib36","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12072-021-10143-4","article-title":"The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040","volume":"15","author":"Ito","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jceh.2026.103525_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1265\/ehpm.24-00365","article-title":"A 4-year cohort study of the effects of PNPLA3 rs738409 genotypes on liver fat and fibrosis and gut microbiota in a non-fatty liver population","volume":"30","author":"Sato","year":"2025","journal-title":"Environ Health Prev Med"},{"key":"10.1016\/j.jceh.2026.103525_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5009\/gnl240407","article-title":"Genetic risk factors for metabolic dysfunction-associated steatotic liver disease","volume":"19","author":"Pei","year":"2025","journal-title":"Gut Liver"}],"updated-by":[{"DOI":"10.1016\/j.jceh.2026.103695","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000}}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688326000575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688326000575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:53:47Z","timestamp":1793922827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688326000575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0973688326000575"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2026.103525","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post Hoc Analysis of a Phase 2 Randomized Trial of Pemafibrate in Metabolic Dysfunction\u2013associated Steatotic Liver Disease: Associations With Platelet Count, Liver Stiffness, and Spleen Volume","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2026.103525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Indian National Association for Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103525"}}